ABSTRACT
Background Intravenous thrombolysis (IVT) with alteplase or tenecteplase prior to mechanical thrombectomy (MT) is the recommended treatment for large-vessel occlusion acute ischemic stroke (LVOS). There are divergent data on whether these agents differ in terms of early recanalization (ER) rates before MT, and little data on their potential differences in terms of established ER predictors such as time elapsed between IVT and ER evaluation (IVT-to-EReval time), occlusion site and thrombus length.
Methods We compared the likelihood of ER after IVT with tenecteplase or alteplase in anterior circulation LVOS patients from the PREDICT-RECANAL (alteplase) and TETRIS (tenecteplase) French multicenter registries. ER was defined as a modified thrombolysis in cerebral infarction score 2b-3 on first angiographic run or non–invasive vascular imaging (magnetic resonance or computed tomography angiography) in patients with early neurological improvement. Analyses were based on propensity score overlap weighting (PSOW, leading to an exact balance in baseline characteristics between the treatment groups) and confirmed with adjusted logistic regression (sensitivity analysis).
Results A total of 1865 patients were included. ER occurred in 156/787 (19.8%) and 199/1078 (18.5%) patients treated with tenecteplase or alteplase, respectively (odds ratio, 1.09 [95%CI 0.83–1.44]; P=0.52). A differential effect of tenecteplase vs alteplase on the probability of ER according to thrombus length was observed (Pinteraction=0.003), with tenecteplase being associated with higher odds of ER in thrombi > 10 mm (odds ratio, 2.43 [95% CI 1.02-5.81]; P=0.04). There was no differential effect of tenecteplase vs alteplase on the likelihood of ER according to the IVT-to-EReval time (Pinteraction=0.40) or occlusion site (Pinteraction=0.80).
Conclusion Both thrombolytics achieved ER in a fifth of LVOS patients, with potentially greater effect of tenecteplase in larger thrombi. There was no significant differential influence of IVT-to-EReval time or occlusion site on likelihood of ER.
Competing Interest Statement
Funding Statement
This research has received funding from the DMU Neurosciences of the APHP.Sorbonne Université and the "Investissements d'avenir" ANR-10-IAIHU-06.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Sorbonne University Research Ethics Committee (CER-2021-1053).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Nonstandard Abbreviations and Acronyms
- AcT
- Alteplase compared to Tenecteplase trial
- ASMD
- absolute standardized mean difference
- ASPECTS
- Alberta Stroke Program Early CT Score
- CTA
- Computed tomography angiography
- CSC
- comprehensive stroke center
- DSA
- digital subtraction angiography
- DWI
- diffusion-weighted imaging
- ER
- early recanalization
- EXTEND-IA TNK
- Tenecteplase versus Alteplase before Endovascular Therapy for Ischemic Stroke trial
- FLAIR
- fluid-attenuated inversion recovery
- ICA
- internal carotid artery
- IVT
- intravenous thrombolysis
- IVT-to-EReval time
- time between intravenous thrombolysis start and evaluation of early recanalization
- LVOS
- large-vessel occlusion acute ischemic stroke
- MCA
- middle cerebral artery
- MT
- mechanical thrombectomy
- NIHSS
- National Institutes of Health Stroke Scale
- mTICI
- modified Thrombolysis in Cerebral infarction
- PSC
- primary stroke center
- PSOW
- propensity score overlap weighting
- SVS
- susceptibility vessel sign
- TETRIS
- Tenecteplase Treatment in Ischemic Stroke
